Table 3. Biologicals approved in Germany, Austria, Luxembourg, and Switzerland for use in allergic diseases.
| Agent | Target | Indication | Self-administration |
|---|---|---|---|
| Omalizumab Xolair® | IgE | IgE-mediated asthma (≥ 6 years) Chronic spontaneous urticaria (≥ 12 years) |
Yes (Switzerland: No) |
| Mepolizumab Nucala® | IL-5 | Asthma (≥ 6 years; Switzerland: > 12 years) EGPA (only in Switzerland: ≥ 18 years) |
Yes |
| Reslizumab CINQAERO® | IL-5 | Asthma (≥ 18 years) | No |
| Benralizumab Fasenra® | IL-5 receptor | Asthma (≥ 18 years) | Yes |
| Dupilumab Dupixent® | IL-4 receptor (shared IL-4/IL-13 receptor) |
CRSwNP (≥ 18 years) Atopic dermatitis (≥ 12 years) Asthma (≥ 12 years) (Switzerland: approval pending) |
Yes |
EGPA = eosinophilic granulomatosis with polyangiitis; CRSwNP = chronic rhinosinusitis with nasal polyps.